Psychemedics Corporation
PMD · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $4 | $5 | $5 | $5 |
| % Growth | -14.5% | 9.5% | -11.7% | – |
| Cost of Goods Sold | $3 | $3 | $3 | $3 |
| Gross Profit | $1 | $2 | $2 | $2 |
| % Margin | 31.4% | 39.4% | 32.8% | 39.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $1 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $3 | $2 | $3 |
| Operating Income | $0 | -$1 | -$1 | -$1 |
| % Margin | 3.8% | -11.5% | -19% | -10.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$1 | -$1 | -$1 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | $0 | -$1 | -$1 | -$1 |
| % Margin | 4.3% | -10.3% | -17.5% | -12.8% |
| EPS | 0.032 | -0.091 | -0.14 | -0.12 |
| % Growth | 135.2% | 35.1% | -16.7% | – |
| EPS Diluted | 0.032 | -0.091 | -0.14 | -0.12 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $1 | -$1 | -$0 | -$0 |
| % Margin | 13.2% | -11.5% | -5% | -0.3% |